FDA Eyes Bacteria Boost for Animal Feed: Farmers Rejoice?
Published Date: 8/19/2025
Proposed Rule
Summary
Evonik Corporation wants the FDA to approve a new safe ingredient called Bacillus velezensis for animal food, which can be used for all kinds of animals. This change could help farmers and pet owners by improving animal feed options. The FDA is reviewing this petition now, so keep an eye out for updates that might affect animal food rules and safety.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Petition to Allow New Animal Feed Ingredient
The FDA filed a petition from Evonik Corporation asking to allow Bacillus velezensis as a source of viable (live) microorganisms in animal food for all species. The petition says this could help farmers and pet owners by improving animal feed options. The FDA is currently reviewing the petition, so this is a proposed change under consideration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16728, Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer
The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Cystoscopic system intended as an aid for detection of bladder cancer," along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16727, Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), all postamendments class III (premarket approval) devices, into class II (special controls), subject to premarket notification. FDA is also establishing a new device classification regulation, along with the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of this device type.
Previous / Next Documents
Previous: 2025-15776, Airworthiness Directives; Airbus Helicopters
If you fly certain Airbus AS 332L2 or EC 225LP helicopters, new safety rules are coming your way! The FAA wants you to keep doing inspections but also add a cool new upgrade to the main gearbox parts to keep things safe. You’ll need to act on this soon, and it might cost some time and money, but it’s all about keeping your chopper flying safely.
Next: 2025-15818, Modernizing the Commission's National Environmental Policy Act Rules
The FCC wants to update its environmental review rules to make building new tech infrastructure faster and easier. This helps companies get projects done quicker, boosting competition and new technology for everyone. If you’re applying for FCC approval, expect clearer, speedier reviews soon!